Literature DB >> 15139867

Comparison of acute lethal toxicity of commonly abused psychoactive substances.

Robert S Gable1.   

Abstract

AIMS: To determine the acute lethal toxicity of a range of psychoactive substances in terms of the dose customarily used as a single substance for non-medical purposes. DESIGN AND
METHOD: A structured English-language literature search was conducted to identify experimental studies and clinical reports that documented human and non-human lethal doses of 20 abused substances that are distributed widely in Europe and North America. Four inclusion criteria were specified for the reports, and approximately 3000 relevant records were retrieved from search engines at Biosis, Science Citation Index, Google and the National Library of Medicine's Gateway. In order to account for different drug potencies, a 'safety ratio' was computed for each substance by comparing its reported acute lethal dose with the dose most commonly used for non-medical purposes.
FINDINGS: The majority of published reports of acute lethal toxicity indicate that the decedent used a co-intoxicant (most often alcohol). The calculated safety ratios varied between substances by more than a factor of 100. Intravenous heroin appeared to have the greatest direct physiological toxicity; several hallucinogens appeared to have the least direct physiological toxicity.
CONCLUSIONS: Despite residual uncertainties, the substantial difference in safety ratios suggests that abused substances can be rank-ordered on the basis of their potential acute lethality.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15139867     DOI: 10.1111/j.1360-0443.2004.00744.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  42 in total

1.  Typologies of cannabis users and associated characteristics relevant for public health: a latent class analysis of data from a nationally representative Canadian adult survey.

Authors:  Benedikt Fischer; Jürgen Rehm; Hyacinth Irving; Anca Ialomiteanu; Jean-Sebastien Fallu; Jayadeep Patra
Journal:  Int J Methods Psychiatr Res       Date:  2010-06       Impact factor: 4.035

2.  Ultra-structural hair alterations of drug abusers: a scanning electron microscopic investigation.

Authors:  Fatma Pinar Turkmenoglu; Ugur Baran Kasirga; Hakan Hamdi Celik
Journal:  Int J Clin Exp Med       Date:  2015-06-15

3.  Interactions of benzodiazepines with heroin: Respiratory depression, temperature effects, and behavior.

Authors:  Anum Afzal; Eugene A Kiyatkin
Journal:  Neuropharmacology       Date:  2019-06-19       Impact factor: 5.250

Review 4.  Post-mortem clinical pharmacology.

Authors:  R E Ferner
Journal:  Br J Clin Pharmacol       Date:  2008-05-29       Impact factor: 4.335

5.  Nonmedical opioid use and heroin use in a nationally representative sample of us high school seniors.

Authors:  Joseph J Palamar; Jenni A Shearston; Eric W Dawson; Pedro Mateu-Gelabert; Danielle C Ompad
Journal:  Drug Alcohol Depend       Date:  2015-11-21       Impact factor: 4.492

Review 6.  Human hallucinogen research: guidelines for safety.

Authors:  Mw Johnson; Wa Richards; Rr Griffiths
Journal:  J Psychopharmacol       Date:  2008-07-01       Impact factor: 4.153

7.  Brain temperature effects of intravenous heroin: State dependency, environmental modulation, and the effects of dose.

Authors:  R Aaron Bola; Eugene A Kiyatkin
Journal:  Neuropharmacology       Date:  2017-07-27       Impact factor: 5.250

8.  Increasing Willingness to Use Synthetic Drugs if Offered among Electronic Dance Music Party Attendees, 2017-2019.

Authors:  Joseph J Palamar
Journal:  J Psychoactive Drugs       Date:  2020-05-19

9.  Psilocybin, psychological distress, and suicidality.

Authors:  Peter S Hendricks; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2015-09       Impact factor: 4.153

Review 10.  The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.

Authors:  Matthew W Johnson; Roland R Griffiths; Peter S Hendricks; Jack E Henningfield
Journal:  Neuropharmacology       Date:  2018-06-05       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.